Preventing infections in newborns by targeting immune cells
Prevention of Neonatal Sepsis by Therapeutic Targeting of MDSCs
This study is looking at how certain immune cells in preterm babies can make them more prone to infections like sepsis, and it aims to find ways to boost their immune system early on to help keep them healthier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11039939 on NIH RePORTER |
What this research studies
This research investigates how certain immune cells, known as myeloid-derived suppressor cells (MDSCs), affect the vulnerability of newborns to infections like sepsis. The study focuses on preterm infants, who are at a higher risk of severe infections due to their immature immune systems. By administering specific immunomodulatory agents early in life, the researchers aim to enhance the immune response and reduce the risk of sepsis. The approach involves understanding the balance between inflammation and immune suppression in newborns to improve their overall health outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are preterm infants, particularly those born at or below 37 weeks of gestation.
Not a fit: Patients who are full-term infants or older children may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of neonatal sepsis and improve survival rates among preterm infants.
How similar studies have performed: Previous research has shown promise in targeting immune cells to enhance responses in various infections, suggesting potential success for this novel approach in neonates.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Larson, Shawn David — University of Florida
- Study coordinator: Larson, Shawn David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.